News & Resources

Olshan Client Pharmacyclics Featured in Numerous Media Reports Announcing First Commercial Drug Approved by FDA

November 13, 2013

The Wall Street Journal, The New York Times and numerous other media outlets reported on the U.S. Food and Drug Administration’s (FDA) approval of Pharmacyclics’ first commercial drug  IMBRUVICA™, as treatment for patients with a rare blood cancer called mantle cell lymphoma. The highly anticipated new cancer drug has attracted considerable attention from doctors, investors and Wall Street analysts. Olshan Partner Adam Finerman, Of Counsel Jonathan Deblinger and Associate Marisa Lusthaus represent Pharmacyclics in connection with its corporate and securities matters.

Practice Areas